MedTrace Logo

Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy

NCT01316458 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2017-06-01

No results posted yet for this study

Summary

To investigate the ability of 600 mg of Glivec®, given once daily by mouth to patients with rising PSA following radical prostatectomy, to produce a sustained biochemical response during the first 6 months of treatment.

Conditions

  • Prostatic Neoplasm
  • Genital Neoplasms, Male
  • Neoplasms, Abdominal
  • Urogenital Neoplasms
  • Genital Diseases, Male
  • Prostatic Diseases
  • Antineoplastic Agents
  • Imatinib

Interventions

DRUG

STI571 (Glivec®)

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2010-07-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01316458 on ClinicalTrials.gov